CDXS
Price
$2.29
Change
-$0.20 (-8.03%)
Updated
Apr 3 closing price
Capitalization
189.7M
27 days until earnings call
ELDN
Price
$3.16
Change
-$0.15 (-4.53%)
Updated
Apr 3 closing price
Capitalization
198.21M
34 days until earnings call
Ad is loading...

CDXS vs ELDN

Header iconCDXS vs ELDN Comparison
Open Charts CDXS vs ELDNBanner chart's image
Codexis
Price$2.29
Change-$0.20 (-8.03%)
Volume$1.45M
Capitalization189.7M
Eledon Pharmaceuticals
Price$3.16
Change-$0.15 (-4.53%)
Volume$198.66K
Capitalization198.21M
CDXS vs ELDN Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. ELDN commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Buy and ELDN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CDXS: $2.29 vs. ELDN: $3.15)
Brand notoriety: CDXS and ELDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 150% vs. ELDN: 83%
Market capitalization -- CDXS: $189.7M vs. ELDN: $198.21M
CDXS [@Biotechnology] is valued at $189.7M. ELDN’s [@Biotechnology] market capitalization is $198.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileELDN’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • ELDN’s FA Score: 1 green, 4 red.
According to our system of comparison, ELDN is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while ELDN’s TA Score has 4 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 5 bearish.
  • ELDN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than ELDN.

Price Growth

CDXS (@Biotechnology) experienced а -21.58% price change this week, while ELDN (@Biotechnology) price change was -7.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

CDXS is expected to report earnings on May 01, 2025.

ELDN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELDN($198M) and CDXS($190M) have the same market capitalization . ELDN YTD gains are higher at: -23.301 vs. CDXS (-51.992). CDXS (-53.41M) and ELDN (-55.85M) have comparable annual earnings (EBITDA) . ELDN has more cash in the bank: 78.2M vs. CDXS (73.5M). ELDN has less debt than CDXS: ELDN (501K) vs CDXS (59.9M). CDXS has higher revenues than ELDN: CDXS (59.3M) vs ELDN (0).
CDXSELDNCDXS / ELDN
Capitalization190M198M96%
EBITDA-53.41M-55.85M96%
Gain YTD-51.992-23.301223%
P/E RatioN/A4.81-
Revenue59.3M0-
Total Cash73.5M78.2M94%
Total Debt59.9M501K11,956%
FUNDAMENTALS RATINGS
CDXS vs ELDN: Fundamental Ratings
CDXS
ELDN
OUTLOOK RATING
1..100
708
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9817
PRICE GROWTH RATING
1..100
8753
P/E GROWTH RATING
1..100
10073
SEASONALITY SCORE
1..100
n/a36

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (42) in the Chemicals Specialty industry is in the same range as ELDN (43) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to ELDN’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as ELDN (100) in the Pharmaceuticals Major industry. This means that CDXS’s stock grew similarly to ELDN’s over the last 12 months.

ELDN's SMR Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for CDXS (98) in the Chemicals Specialty industry. This means that ELDN’s stock grew significantly faster than CDXS’s over the last 12 months.

ELDN's Price Growth Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for CDXS (87) in the Chemicals Specialty industry. This means that ELDN’s stock grew somewhat faster than CDXS’s over the last 12 months.

ELDN's P/E Growth Rating (73) in the Pharmaceuticals Major industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that ELDN’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSELDN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
85%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ELDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRMSX35.04N/A
N/A
T. Rowe Price Emerging Markets Stock
HSZYX5.99N/A
N/A
NexPoint Climate Tech Y
IVIPX40.82N/A
N/A
VY® Invesco Equity and Income S2
SSIQX11.86N/A
N/A
State Street International Stock Sel K
QLSCX24.69N/A
N/A
Federated Hermes MDT Small Cap Core R6

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
-8.03%
DNLI - CDXS
46%
Loosely correlated
-6.91%
ABCL - CDXS
44%
Loosely correlated
-5.86%
XENE - CDXS
44%
Loosely correlated
-2.38%
AXON - CDXS
43%
Loosely correlated
-3.35%
BEAM - CDXS
42%
Loosely correlated
-10.93%
More

ELDN and

Correlation & Price change

A.I.dvisor tells us that ELDN and ZURA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELDN and ZURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELDN
1D Price
Change %
ELDN100%
-4.53%
ZURA - ELDN
32%
Poorly correlated
-7.26%
CDXS - ELDN
31%
Poorly correlated
-8.03%
AMLX - ELDN
31%
Poorly correlated
-7.14%
SYRE - ELDN
30%
Poorly correlated
-9.68%
MDGL - ELDN
28%
Poorly correlated
-2.24%
More